β2 adrenergic receptor agon 
Welcome,         Profile    Billing    Logout  
 50 Companies  89 Products   89 Products   263 Diseases   194 Trials   10643 News 
310 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
formoterol fumarate  (PT005) / AstraZeneca
2008-002844-40: A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS

Ongoing
4
20
Europe
CHF 718 HFA, CHF 718 HFA, Atimos, Foster, Atimos, Foster
Leiden University Medical Center
astma
 
 
2004-000755-41: A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthma

Ongoing
3
34
Europe
Formoterol Fumarate, Foradil 12µg poudre pour inhalation, CHF 1531, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation
Chiesi Farmaceurtici S.p.A
Children Persistent Asthma
 
 
2005-002538-37: Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease.

Ongoing
2
30
Europe
Formoterol 12 mcg capsules, Foradil Aerolizer, Foradil, Foradil
Pharmachemie B.V.
mild to moderate reversible obstructive airways disease
 
 
2007-004377-26: Effect of fixed combination of beclomethasone dipropionate/formoterol fumarate (BDP/FF), as reliever, upon exhaled nitric oxide in asthma. FENOMENO study (Fractional Exhaled Nitric Oxide-Multiple Expiration flow of NO). A single-centre, placebo controlled, randomized, double blind, cross-over study

Ongoing
2
20
Europe
Foster, Salbutamol, CHF 1535 HFA pMDI, Foster, Ventolin, Foster, Ventolin
Chiesi Farmaceutici S.p.A.
Moderate asthma
 
 
albuterol sulfate / Generic mfg.
NCT06154304: BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

Not yet recruiting
3
120
US
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Albuterol Test Product, Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Albuterol Reference Product, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Cipla Ltd.
Bronchial Asthma
08/24
09/24
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

Completed
3
64
RoW
Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI
AstraZeneca
Asthma, Exercise-Induced
06/24
06/24
NCT06618105: Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd

Not yet recruiting
3
144
RoW
Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations, Albuterol Sulfate, Test Placebo, Placebo, Reference Placebo
Macleods Pharmaceuticals Ltd
Mild Asthma
05/25
05/25
NCT06664619: A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Recruiting
3
724
US
Fp/ABS, fluticasone propionate/albuterol sulfate combination, FP, fluticasone propionate, ABS, albuterol sulfate, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
05/26
05/26
NCT06052267: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Active, not recruiting
3
2196
Europe, Canada, US, RoW
TEV-56248, Albuterol sulfate
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
07/26
07/26
NCT06271408: Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Recruiting
1
6
US
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Solo VMN, Metered Dose Inhaler, pMDI-aerosol metered dose inhaler, Jet Nebulizer, JN nebulizer
Polarean, Inc., Aerogen
Chronic Obstructive Pulmonary Disease
04/24
04/24
NCT04901715: Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

Recruiting
1
30
US
Albuterol, ProAir HFA (hydrofluoroalkane) Inhaler, Ventolin HFA (hydrofluoroalkane) Inhaler, Technetium99m - Sulfur Colloid (Tc99m-SC)
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Primary Ciliary Dyskinesia
04/25
04/25
NCT06290102: Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Completed
1
30
US
TEV-56248, - fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI), Fp MDPI, - fluticasone propionate multidose dry powder inhaler
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
10/24
10/24
NCT05035862: Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

Recruiting
1
12
US
Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells, Prednisone
Emory University, The Marcus Foundation, Ossium Health, Inc.
Asthma
07/25
12/25
NCT05241288: Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

Completed
N/A
54
US
Albuterol eMDPI DS, ProAir® Digihaler®
University of North Carolina, Chapel Hill, Wake Forest University Health Sciences, Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
02/23
02/23
NCT04912596: Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma

Recruiting
N/A
148
RoW
Albuterol Sulfate inhalation aerosol 108 mcg per actuation, Albuterol Sulfate, Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation, Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo, Albuterol Sulfate inhalation Placebo, Methacholine
Intech Biopharm Ltd.
Mild Asthma
01/25
06/25
ACTRN12613000836730: Albuterol for Acute Lung Injury

Recruiting
N/A
50
 
south valley university , south valley university, Qena university hospital
we will study the effect of adding aerosolized albuterol to lung recruitment maneuver during the managment of ALI due to surgical and non-surgical causes e.g acute lung injury following aspiration pneumonia , abdominal sepsis, pancreatitis, chest trauma , lobectomy,and so on
 
 
Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
2019-003082-17: How electronic monitoring and feedback affect use of Easyhaler asthma medication. Wie sich elektronische Kontrolle und Rückmeldung auf die Einnahme der Easyhaler-Asthmamedikation auswirken

Not yet recruiting
4
166
Europe
Inhalation powder, Budesonid Orion Easyhaler 0,2 mg/Dosis, Budesonid Orion Easyhaler 0,4 mg/Dosis, Bufori Easyhaler 160 Mikrogramm/4,5 Mikrogramm, Bufori Easyhaler 320 Mikrogramm/9 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/250 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/500 Mikrogramm, Salbu Easyhaler 0,2 mg/Dosis
Orion Corporation Orion Pharma, Orion Corporation Orion Pharma
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-001573-22: Use of Buventol and Bufomix Easyhaler in methacholine challenge andtheir effect on inhalation profiles in experimentally induced asthma attacks Buventol ja Bufomix Easyhalerin käyttö metakoliinialtistuksen avaavana lääkkeenä sekä niiden vaikutus sisäänhengitysprofiileihin kokeellisesti aiheutetussa astmakohtauksessa

Not yet recruiting
4
180
Europe
Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation pMDI, Inhalation powder, Inhalation solution, Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation
Orion Corporation, Orion Corporation
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
EASYRELIEF, NCT05084222 / 2021-001573-22: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

Completed
4
180
Europe
Buventol® Easyhaler® 200 µg/inhalation dmDPI, Salbutamol 200 µg/dose dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Budesonide/formoterol 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI, Salbutamol 100 µg/dose MDI
Orion Corporation, Orion Pharma, Orion Corporation
Asthma
06/23
06/23
budesonide/formoterol / Generic mfg.
ACTRN12622000232730p: Monitoring Intermittent vs Regular inhaled corticoSteroids in asthma: MIRSA study

Not yet recruiting
4
135
 
Dr John D Brannan, GlaxoSmithKline
Asthma
 
 
ACTRN12622000232730: Monitoring Intermittent vs Regular inhaled corticoSteroids in asthma: MIRSA study

Not yet recruiting
4
135
 
Dr John D Brannan, GlaxoSmithKline
Asthma
 
 
2005-005874-65: Non-invasive monitoring of airway inflammation in asthmatic patients during adaptation of inhaled steroid therapy

Ongoing
4
40
Europe
Symbicort Turbohaler, Inhalation powder
University Hospital Antwerp
asthma
 
 
ChiCTR-TRC-10000969: Chronic obstructive pulmonary disease(COPD): clinical study of Symbicort Turbuhaler combined Theophylline

Completed
4
100
 
Symbicort 160/4.5ug/breathing, 2 breathing/time, twice a day+theophylline 0.1g - 0.2g twice a day +Ventolin 100ug/breathing, prn ;Symbicort 160/4.5ug/breathing, 2 breathing/time, twice a day+Ventolin 100ug/breathing, prn
1st Affiliated Hospital of SYSU; Level of the institution：, s
Chronic obstructive pulmonary disease(COPD)
 
 
2014-001029-34: The inhaled combination of budesonide-formoterol consists a basic asthma treatment.A helpful specific index for the prognosis of future exacerbation risk and deterioration of lung function,is the Exhaled Nitric Oxide.The objective of the current study is the evaluation of Pulmoton- Elpenhaler in Exhaled Nitric Oxide of patients with bronchial asthma. Ο εισπνεόμενος συνδυασμός βουδεσονίδης-φορμοτερόλης αποτελεί τη βασική θεραπεία για το άσθμα. Ένας ειδικός δείκτης που βοηθά στην πρόγνωση μελλοντικού κινδύνου παρόξυνσης και μείωσης της λειτουργίας των πνευμόνων, είναι το εκπνεόμενο μονοξείδιο του αζώτου.Η παρούσα μελέτη έχει ως κύριο σκοπό την αξιολόγηση της επίδρασης του εισπνεόμενου συνδυασμού βουδεσονίδης-φορμοτερόλης (Pulmoton® Elpenhaler®) στο εκπνεόμενο μονοξείδιο του αζώτου ασθενών με βρογχικό άσθμα.

Ongoing
4
108
Europe
Pulmoton/Elpenhaler, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler
ELPEN Pharmaceutical Co. Inc, ELPEN Pharmaceutical Co. Inc.
Bronchial Asthma Bρογχικό Άσθμα
 
 
2018-003467-64: A 24-week Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using Salbutamol or AntiInflammatory Reliever (SYMBICORT®) as rescue medication in addition to SYMBICORT as daily asthma controller.

Not yet recruiting
4
80
Europe
Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, Inhalation powder, Symbicort® Turbohaler®
Astra Zeneca AB, Astra Zeneca AB
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ChiCTR1800020279: Clinical trial for step-down therapy in patients with mild to moderate asthma

Recruiting
4
100
 
budenide 200μg qd+SABA prn ;symbicort 80/4.5μg qd+prn ;symbicort 80/4.5μg prn ;symbicort 80/4.5μg prn ;SABA prn
West China Hospital, Sichuan University; West China Hospital, Sichuan University, latitudinal project funds
bronchial asthma
 
 
SHAMAL, NCT04159519 / 2019-001924-37: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed
4
170
Europe
Symbicort®, budesonide/formoterol, Fasenra®, benralizumab, Ventolin®, salbutamol
AstraZeneca
Asthma, Severe Eosinophilic Asthma
01/23
01/23
ChiCTR2100048845: Comparison of Budesonide, Symbicort and Triple Nebulized Drugs in Improving Perioperative Airway Function of Chronic Sinusitis

Recruiting
4
300
 
Budesonide ;Symbicort ;Triple Nebulized Drugs
Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital, National Natural Science Foundation of China (82071021)
chronic nasosinusitis
 
 
MIT-AIR, NCT06568445: Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy

Not yet recruiting
4
90
RoW
Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）, maintenance at initial treatment sequential as-needed therapy group, as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）, As-needed therapy group
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bronchial Asthma
04/27
09/27
NCT01225913: Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Recruiting
4
50
US
fluticasone/salmeterol in all asthmatics, symbicort 80/4.5, advair 100/50 or 250/50 or 500/50 bid, budesonide/formoterol or fluticasone/salmeterol in all asthmatics, symbicort 160/4.5, advair 250/50
Gelb, Arthur F., M.D.
Asthma
06/27
06/27
ChiCTR2400088138: Efficacy of ICS-Formoterol Maintenance at Initial Treatment with Sequential Anti-Inflammation Reliever Therapy in Newly Diagnosed Mild Asthma Patients: A Randomized, Parallel, Positive-Control Study

Not yet recruiting
4
90
 
Inhaled budesonide-formoterol as needed when symptoms are present (Symbicort 160/4.5) ?）， No more than 8 puffs per day, continuous to 24W.; budesonide 160 μg-formoterol 4.5 μg, administered as one inhalation twice daily for maintenance for 4W, sequential as-needed therapy to 24W.
Shanghai General Hospital; Shanghai General Hospital, Clinical Research Innovation Plan of Shanghai General Hospital;China International Medical Foundation-Practical Research Project on Respiratory Diseases
mild bronchial asthma
 
 
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme

Not yet recruiting
3
102
Europe
, Inhalation powder, pre-dispensed, Bricanyl, Symbicort
Centre Hospitalier Intercommunal de Créteil, Astrazeneca
moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ACTRN12622001217796: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma.

Recruiting
3
400
 
Medical Research Institute of New Zealand, AstraZeneca Ltd
Asthma
 
 
ChiCTR-TRC-08000215: Chronic obstructive pulmonary disease(COPD)--Symbicort Turbuhaler clinical study

Completed
3
450
 
Symbicort? 160/4.5ug/breathing, 2 breathing/time, 2 times/day+Symbicort?160/4.5ug/breathing, prn ;Symbicort 160/4.5ug/breathing, 2 breathing/time, 2 times/day + Turbuhaler 100ug/breathing, prn ;Si Lihua 18ug/breathing, 1 breathing/time, 1 time/day + Auccitub 12ug/breathing, 2 times/day, and Turbuhaler 100ug/breathing, prn
The First Affiliated Hospital of Sun Yat-sen University; 2nd and 3rd Affiliated Hospital of SYSU, Department of Statistics of School of Public Health of SYSU, Sun Yat-sen University
Chronic obstructive pulmonary disease(COPD)
 
 
ChiCTR-TRC-09000566: Mild Asthma--as-needed Symbicort Turbuhaler clinical study

Completed
3
450
 
one inhalation of Pulmicort Turbuhaler 200 ug/inhalation ;Oxis Turbuhaler 4.5 ug/inhalation with symptom-driving ;Symbicort Turbuhaler 160/4.5 ug/inhalation with symptom-driving
1st Affiliated Hospital of SYSU; 2nd and 3rd Affiliated Hospital of SYSU, 1st Affiliated Hospital of SYSU
mild asthma
 
 
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva.

Ongoing
3
200
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG
GlaxoSmithKline Research and Development, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
 
 
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma.

Ongoing
3
675
Europe
Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms
Medical Research Institute of New Zealand, Astra Zeneca
Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation

Terminated
3
102
Europe
Budesonide Formoterol Drug Combination, nebulisation of terbutaline
Centre Hospitalier Intercommunal Creteil, AstraZeneca
Asthma in Children
09/21
06/23
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

Completed
3
1485
US
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg
Cipla Ltd.
Asthma
08/23
08/23
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma

Completed
3
644
Europe, Canada, Japan, US, RoW
BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH
AstraZeneca
Asthma
02/25
02/25
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting
3
300
Europe, Canada, US, RoW
Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
AstraZeneca, Fortrea
Severe Asthma
06/27
06/27
KALOS, NCT04609878 / 2020-001520-34: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2266
Europe, Canada, Japan, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca, AstraZeneca AB
Asthma
03/25
03/25
LOGOS, NCT04609904 / 2020-001521-31: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2182
Europe, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca
Asthma
03/25
03/25
ChiCTR2500098432: Single dose, fasting, randomized, open label bioequivalence study of budesonide fomotro inhaled aerosol in healthy subjects

Completed
1
40
 
T-R-T-R Test preparation (T): budesonide formoterol inhalation aerosol, the specification is the main drug content per bottle: 120 bottles per bottle, 181 g of budesonide per bottle, 5.1 g of formoterol fumarate, delivery dose: 120 bottles per bottle, 160 g of budesonide per bottle, 4.5 g of formoterol fumarate. Produced and supplied by Sichuan Pritech Pharmaceutical Co., Ltd. Reference preparation (R): budesonide formoterol inhalation aerosol (trade name: SYMBICORT?), specification is 120 puffs per bottle, each puff contains budesonide 181 g, formoterol fumarate 5.1 g, and 160 g of budesonide and 4.5 g of formoterol fumarate per pinch outside the driver. Produced by AstraZeneca and supplied by Sichuan Pritech Pharmaceutical Co., Ltd.; R-T-R-T Test preparation (T): budesonide formoterol inhalation aerosol, the specification is the main drug content per bottle: 120 bottles per bottle, 181 g of budesonide per bottle, 5.1 g of formoterol fumarate, delivery dose: 120 bottles per bottle, 160 g of budesonide per bottle, 4.5 g of formoterol fumarate. Produced and supplied by Sichuan Pritech Pharmaceutical Co., Ltd. Reference preparation (R): budesonide formoterol inhalation aerosol (trade name: SYMBICORT?), specification is 120 puffs per bottle, each puff contains budesonide 181 g, formoterol fumarate 5.1 g, and 160 g of budesonide and 4.5 g of formoterol fumarate per pinch outside the driver. Produced by AstraZeneca and supplied by Sichuan Pritech Pharmaceutical Co., Ltd.
Beijing Shijitan Hospital, Capital Medical University; Sichuan Purity Pharmaceutical Co., Ltd., Sichuan Purity Pharmaceutical Co., Ltd.
chronic obstructive pulmonary disease
 
 
ChiCTR1800017584: Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease

Completed
N/A
180
 
Budesonide/formoterol (Symbicort; 160 μg/4.5 μg; 1 suction/time, 2 times/day); treatment of tiotropium bromide (Spiriva; 1.8 μg inhaled once a day before sleeping). ;Bbudesonide/formoterol (Symbicort; 160 μg/4.5 μg; 1 suction/time, 2 times/day).
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, None
Moderate to severe chronic obstructive pulmonary disease
 
 
ChiCTR1800019852: The efficacy of budesonide/formoterol in cough variant asthma: A Multi-center Randomized, Controlled Clinical Trial

Recruiting
N/A
500
 
budesonide/formoterol (Symbicort) 160/4.5ug 2 inhalation bid* 3 months ;budesonide/formoterol (Symbicort) 160/4.5ug 1 inhalation bid* 3 months
Second Affiliated Hospital, Zhejiang University School of Medicine; Second Affiliated Hospital, Zhejiang University School of Medicine, support by AstraZeneca
cough variant asthma
 
 
ChiCTR2000030452: Multicenter prospective randomized controlled trial for Dong-Tian Chang-Chun Ointment in the treatment of stable COPD patients

Not yet recruiting
N/A
96
 
Dongtian Changchun Ointment+Symbicort Turbuhaler ;Symbicort Turbuhaler
Zhongshan Hospital Affiliated Fudan University; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Zhongshan Hospital Affiliated Fudan University, Key projects for prevention and control of chronic noncommunicable diseases in the 13th five-year plan of the ministry of science and technology
Chronic obstructive pulmonary disease
 
 
ChiCTR2000036980: Clinical study on the effect of Sansang Shenqi Decoction on airway function in patients with chronic obstructive pulmonary disease at stable period

Recruiting
N/A
200
 
Sansang Shenqi Decoction+Symbicort Turbuhaler ;Symbicort Turbuhaler
LongHua Hospital Shanghai University of Traditional Chinese Medicine; Level of the institution：, Shanghai Shenkang Hospital Development Center
chronic obstructive pulmonary disease
 
 
NCT06105671: U-LABA/ICS Effects on Exercise Performance, Formoterol

Completed
N/A
20
Europe
Symbicort, Formoterol, Placebo, Mannitol
Morten Hostrup, PhD
Exercise Performance
07/24
07/24
NCT00576069: Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting
N/A
60
US
budesonide/formoterol, symbicort 80/4.5, symbicort 160/4.5, budesonide 80 or 160ug/formoterol 4.5ug, 2 inhalations bid, spiriva handihaler or respihaler, fluticasone/salmeterol, advair 100/50, advair 250/50, mometasone/formoterol, Dulera, Prednisone, medrol
Gelb, Arthur F., M.D.
Asthma
06/27
06/27
Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
2022-003784-15: Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient. Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable.

Not yet recruiting
4
35
Europe
Trixéo Aerosphere, BGF 160, Suspension and solution for spray, Trixeo Aérosphère
CHU DE LILLE, AstraZeneca
Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable, Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT06571942: Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Recruiting
4
128
RoW
Vilanterol / Umeclidinium (25/62.5 mcg), ANORO, Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), TRELEGY, Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg, TRIMBOW, Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg, TRIXEO
National Institute of Respiratory Diseases, Mexico
COPD Bronchitis, Pollution Related Respiratory Disorder
01/25
01/25
IKANOS, NCT05970263: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Withdrawn
4
1000
NA
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator
AstraZeneca, Iqvia Pty Ltd, Premier Inc.
COPD
12/25
12/25
NCT06905483: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Not yet recruiting
4
28
RoW
Budesonide/Glycopyrronium/Formoterol (BGF), Breztri, Fluticasone Furoate/Umeclidinium/Vilanterol (FUV), Trelegy
Thammasat University
COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
12/25
03/26
INDOS-B, NCT06531798: Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

Not yet recruiting
4
150
NA
Breztri Aerosphere
AstraZeneca
Moderate to Severe COPD
10/26
12/26
2018-001704-10: Phase 3b Study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fuumarate and Glycopyrronium/Formoterol Fumarate on Specific Image based Airway Volumes and Resistance in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Not yet recruiting
3
20
Europe
Budesonide Glycopyrronium Formoterol Fumarate, Glycopyrronium Formoterol Fumarate (GFF), PT010, PT0003, Pressurised inhalation, suspension, Bevespi
AstraZeneca AB, AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD), Diseases [C] - Respiratory Tract Diseases [C08]
 
 
THARROS, NCT06283966: A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting
3
5000
Europe, Canada, Japan, US, RoW
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
03/28
03/28
NCT05573464 / 2022-001476-33: A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Hourglass Jul 2024 - Dec 2024 : Data for COPD
Completed
3
559
Europe, Canada, US, RoW
BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFO, BGF MDI HFA 320/14.4/9.6 μg, BGF MDI HFA
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
03/24
03/24
ATHLOS, NCT06067828: A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Recruiting
3
180
Europe, Canada, US, RoW
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
08/25
08/25
NCT06075095: A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

Recruiting
3
255
Europe, Canada, US, RoW
BGF MDI HFO 320/14.4/9.6μg, Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF), Delivered by MDI HFO (HFO-1234ze), BGF MDI HFA 320/14.4/9.6 μg, Delivered by MDI HFA, Placebo MDI HFA, Placebo
AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
09/25
09/25
VARI-OSCIL, NCT06110403: Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

Recruiting
1/2
35
Europe
TRIXEO AEROSPHERE
University Hospital, Lille, AstraZeneca
Copd
09/25
09/25
NCT05477108: Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Hourglass Jul 2023 - Dec 2023 : Data from trial in healthy volunteers
Completed
1
108
US
Treatment A (BGF MDI HFO with oral activated charcoal), Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFO, Treatment B (BGF MDI HFA with oral activated charcoal), Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
04/23
04/23
NCT05569421: A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Hourglass Feb 2024 - Jun 2024 : Data for healthy volunteers
Completed
1
108
US
Treatment A: BGF MDI HFO, Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFO, Treatment B: BGF MDI HFA, Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
04/23
04/23
NCT06297668: A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Completed
1
42
Europe
Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO, AeroChamber Plus Flow-Vu spacer
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
06/24
06/24
NCT06340581: A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Withdrawn
1
132
NA
Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO, AeroChamber Plus Flow-Vu Spacer
AstraZeneca, Parexel
Healthy
02/25
02/25
NCT06723756: A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Recruiting
1
105
US
Treatment A: BGF MDI HFO, Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFO, Treatment B: BGF MDI HFA, Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Healthy Participants
06/25
06/25
NTproBNP, NCT06317428: NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Recruiting
N/A
29
Europe
Istituto Nazionale di Ricovero e Cura per Anziani
COPD
12/25
12/25
NCT06514144: Exacerbations Among Patients Receiving Breztri (EROS Study)

Completed
N/A
2409
US
BGF, Breztri
AstraZeneca
Pulmonary Disease, Chronic Obstructive, Retrospective Studies
03/23
03/23
ChiCTR2200060625: Perioperative use of budesonide/glycopyrrolate/formoterol MDI for cough relief in patients undergoing thoracic surgery

Not yet recruiting
N/A
30
 
Full use of budesonide/glycopyrrolate/formoterol (1 week before surgery, until discharge after surgery) ;budesonide/glycopyrrolate/formoterol was used postoperatively ;budesonide/glycopyrrolate/formoterol is not used
The first affiliated hospital zhejiang university school of medicine; The first affiliated hospital zhejiang university school of medicine, Third -party funding
Lung Cancer/Cough
 
 
OCT, NCT04675463: The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD

Not yet recruiting
N/A
50
RoW
BGF Inhalation Aerosphere, Breztri, GFF Inhalation Aerosphere, Bevespi
ShiYue Li, AstraZeneca
Pulmonary Disease, Chronic Obstructive
01/23
06/23
EBISU, NCT05219630: Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)

Completed
N/A
106
Japan
AstraZeneca
Pulmonary Disease, Chronic Obstructive
05/23
05/23
NCT05472350: Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy

Not yet recruiting
N/A
128
NA
Breztri Aerosphere, Placebo
Jianxing He
Lung Cancer, Nonsmall Cell, Perioperative, Cough, Drug Effect, Drug Toxicity
08/23
11/23
TORES, NCT04536402: Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

Completed
N/A
3520
RoW
AstraZeneca
Chronic Obstructive Pulmonary Disease
11/23
11/23
MINERVA, NCT06422676: MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA

Active, not recruiting
N/A
4
RoW
AstraZeneca
Chronic Obstructive Pulmonary Disease
12/24
12/24
SKOPOS:MAZI, NCT06744374: A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Completed
N/A
22369
US
BGF, Breztri, MITT, Open triple therapy combination
AstraZeneca
Pulmonary Disease, Chronic Obstructive
03/24
03/24
COnCORD, NCT06368427: Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

Recruiting
N/A
250
Europe
budesonide / glycopyrronium / formoterol
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
09/25
09/25
EROS+CP (US), NCT06742736: EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

Completed
N/A
13000
US
BGF, BREZTRI
AstraZeneca
Pulmonary Disease, Chronic Obstructive
09/24
09/24
RECORD, NCT05311306: REported Outcomes in COPD With Trixeo in Real worlD in Germany

Completed
N/A
475
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/24
07/24
ORESTES, NCT06321731: Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

Completed
N/A
553
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
12/24
12/24
RECORD, NCT05213611: REported Outcomes in COPD With Trixeo in Real worlD

Completed
N/A
148
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/24
07/24
CHOROS, NCT06712563: Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Not yet recruiting
N/A
2000
NA
Budesonide/glycopyrrolate/formoterol fumarate, BGF, Breztri
AstraZeneca, Iqvia Pty Ltd
Pulmonary Disease, Chronic Obstructive
09/26
09/26
CHOROS ORION, NCT05862545: Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

Active, not recruiting
N/A
250
Europe
BGF (budesonide/glycopyrrolate/formoterol fumarate)
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/25
07/25
TRIAENA, NCT05915182: Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

Active, not recruiting
N/A
218
Europe
Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
AstraZeneca
Pulmonary Disease, Chronic Obstructive (COPD)
05/25
05/25
Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
2019-003864-27: Effect of inhalation formulation on uncontrolled asthma

Not yet recruiting
4
70
Europe
Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta
HUS / Mika Mäkelä, Mika Mäkelä
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
AIRLYMPUS, NCT06676319: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Recruiting
2
1000
Europe, Canada, US, RoW
Lunsekimig, SAR443765, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/salmeterol, Budesonide/formoterol
Sanofi
Asthma
10/27
11/27
ChiCTR1800019111: An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects

Recruiting
1
36
 
FLUTIFORM pMDI single-dose administration (50/5 μg, 125/5 μg, and 250/10 μg) and multiple-dose administration (250/10 μg)
West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd
Asthma
 
 
Laevo-Bambuterol (R-bambuterol) / Alvogen
ChiCTR2100043100: Pharmacokinetic study of multiple oral administration of R-Bambuterol hydrochloride tablets in a population with higher plasma butylcholinesterase activity

Recruiting
1
50
 
R-BMB 5mg Q24 for 21 days ;R-BMB 5mg QN for 28 days ;R-BMB 10mg QN for 28 days
Dongguan People's Hospital; Key-Pharma Biomedical Inc., Self-finance
Asthma, COPD
 
 
Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
ChiCTR-TRC-09000442: The effects of salmeterol/fluticasone on circulating biomarker in stable chronic obstructive pulmonary disease

Completed
4
122
 
Ipratropium/albnterol 36/206μg q.i.d (Combivent inhalation aerosol, Boehringer Ingelheim, Inc.) ;50 μg salmeterol and 500 μg fluticasone propionate (Advair Diskus, Seretide, GlaxoSmithKline)
West China Hospital; West China Hospital, Sekf-financing
Chronic obstructive pulmonary disease
 
 
ChiCTR-IPR-16008441: Clinical study on the prevention and treatment of acute altitude sickness by respiratory inhalation drugs

Completed
4
200
 
Budesonide; Ventolin ;Combivent ;physiological salt solution
The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army; The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army, sicentic fundation of the First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army
acute altitude sickness
 
 
2015-000473-12: The effectiveness of single dose Ultibro by Breezhaler versus ipratropium/salbutamol by nebulizer

Not yet recruiting
4
40
Europe
indacaterol maleate/glycopyrronium bromide, ipratropium/salbutamol, QVA149, Inhalation powder, hard capsule, Nebuliser liquid, Ultibro Breezhaler (indacaterol/glycopyrronium), Combivent, salbutamol/ipratropium
UMCG, UMCG, Novartis
COPD, chronic obstructive pulmonary disease, COPD, chronic obstructive pulmonary disease, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ChiCTR-IPR-15006319: Positive end-expiratory pressure device combined with ultrasonic nebulization on the sputum treatment of chronic obstructive pulmonary disease (COPD)

Recruiting
N/A
120
 
positive end-pxpiratory pressure device and combivent ;positive end-pxpiratory pressure device and saline ;ultrasonic nebulization and combivent ;oxgyen nebulization and combivent
The first affiliated hospital of guangzhou medical university; The First Affiliated Hospital of Guangzhou Medical University, NO
chronic obstructive pulmonary disease (COPD)
 
 
ChiCTR2000038403: A clinical study of nebulization of combivent and mannitol for the treatment of bronchiectasis

Recruiting
N/A
60
 
conventional therapy+combivent and mannitol nebulization ;conventional therapy+normal saline nebulization
The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Self financing
Bronchiectasis
 
 
Alenia (budesonide/formoterol) / Ache Lab
NCT02621359: A Two Week Nitazoxanidebased Quadruple Regimen

Recruiting
3
100
RoW
Nitazoxanide, Alenia, nitclean, parazoxanide, Levofloxacin, Tavanic, levoxin, venaxan., Doxycyclin, Vibramycin, Doxymycin, Omeprazole, Omepak, Pepzole, Gasec, Risek.
Tanta University
Dyspepsia
12/22
12/22
ESPIRE, NCT04233190: A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

Completed
3
472
RoW
Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg, fumarato de formoterol di-hidratado 12mcg + budesonida 400mcg/fumarato de formoterol di-hidratado 62mcg + budesonida 200mcg
Eurofarma Laboratorios S.A.
Asthma Copd
10/24
10/24
FORASMA, NCT05735431: Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil

Not yet recruiting
3
132
RoW
Administration of investigation drug, Formoterol 6 mcg/fluticasone 125 mcg, Administration of comparator, Alenia® 6 mcg/200 mcg
Eurofarma Laboratorios S.A.
Moderate Asthma
05/26
07/26
abediterol (AZD-0548) / AstraZeneca
2016-004140-10: A study to investigate the effects of different dose levels of abediterol administered once daily during four weeks to patients with symptomatic asthma on inhaled corticosteroids compared to patients given an open label comparator or placebo. The study will evaluate the efficacy of abediterol, how this study drug is absorbed in the blood stream and how safe and tolerable it is for the patients.

Ongoing
2
600
Europe, RoW
Abediterol, Serevent Accuhaler containing 50 micrograms of salmeterol (as xinafoate), AZD0548, Inhalation powder, Inhalation powder, pre-dispensed, Serevent Accuhaler
AstraZeneca AB, AstraZeneca AB
This study will be performed in men and non-pregnant, non-lactating women, all between 12 and 95 years of age with asthma symptomatic on ICS and fulfilling the reversibility criterion (improvement of FEV1≥12% and 200 mL after administration of salbutamol/albuterol) at Visit 2., Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that episodes of breathing difficulty are still occurring despite the use of other available treatments., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium

Not yet recruiting
3
28
Europe
QMF149, QVM149, Inhalation powder
University Medical Center Groningen, Novartis Pharma AG
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
3
200
Europe, RoW
QMF149, Budesonide
Novartis Pharmaceuticals
Asthma
05/26
06/26
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
formoterol fumarate  (PT005) / AstraZeneca
2008-002844-40: A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS

Ongoing
4
20
Europe
CHF 718 HFA, CHF 718 HFA, Atimos, Foster, Atimos, Foster
Leiden University Medical Center
astma
 
 
2004-000755-41: A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Foradil/Aerolizer) in children with persistent asthma

Ongoing
3
34
Europe
Formoterol Fumarate, Foradil 12µg poudre pour inhalation, CHF 1531, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation, Atismos 12µg pressurised inhalation solution 120 actuations, Foradil 12µg proudre pour inhalation
Chiesi Farmaceurtici S.p.A
Children Persistent Asthma
 
 
2005-002538-37: Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease.

Ongoing
2
30
Europe
Formoterol 12 mcg capsules, Foradil Aerolizer, Foradil, Foradil
Pharmachemie B.V.
mild to moderate reversible obstructive airways disease
 
 
2007-004377-26: Effect of fixed combination of beclomethasone dipropionate/formoterol fumarate (BDP/FF), as reliever, upon exhaled nitric oxide in asthma. FENOMENO study (Fractional Exhaled Nitric Oxide-Multiple Expiration flow of NO). A single-centre, placebo controlled, randomized, double blind, cross-over study

Ongoing
2
20
Europe
Foster, Salbutamol, CHF 1535 HFA pMDI, Foster, Ventolin, Foster, Ventolin
Chiesi Farmaceutici S.p.A.
Moderate asthma
 
 
albuterol sulfate / Generic mfg.
NCT06154304: BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

Not yet recruiting
3
120
US
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Albuterol Test Product, Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Albuterol Reference Product, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Cipla Ltd.
Bronchial Asthma
08/24
09/24
BREATH, NCT06245551: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

Completed
3
64
RoW
Budesonide/albuterol metered-dose inhaler 160/180 μg, PT027 (BDA MDI) 160/180 μg, Placebo metered-dose inhaler, Placebo MDI
AstraZeneca
Asthma, Exercise-Induced
06/24
06/24
NCT06618105: Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd

Not yet recruiting
3
144
RoW
Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations, Albuterol Sulfate, Test Placebo, Placebo, Reference Placebo
Macleods Pharmaceuticals Ltd
Mild Asthma
05/25
05/25
NCT06664619: A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Recruiting
3
724
US
Fp/ABS, fluticasone propionate/albuterol sulfate combination, FP, fluticasone propionate, ABS, albuterol sulfate, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
05/26
05/26
NCT06052267: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Active, not recruiting
3
2196
Europe, Canada, US, RoW
TEV-56248, Albuterol sulfate
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
07/26
07/26
NCT06271408: Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Recruiting
1
6
US
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Solo VMN, Metered Dose Inhaler, pMDI-aerosol metered dose inhaler, Jet Nebulizer, JN nebulizer
Polarean, Inc., Aerogen
Chronic Obstructive Pulmonary Disease
04/24
04/24
NCT04901715: Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

Recruiting
1
30
US
Albuterol, ProAir HFA (hydrofluoroalkane) Inhaler, Ventolin HFA (hydrofluoroalkane) Inhaler, Technetium99m - Sulfur Colloid (Tc99m-SC)
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Primary Ciliary Dyskinesia
04/25
04/25
NCT06290102: Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Completed
1
30
US
TEV-56248, - fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI), Fp MDPI, - fluticasone propionate multidose dry powder inhaler
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
10/24
10/24
NCT05035862: Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

Recruiting
1
12
US
Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells, Prednisone
Emory University, The Marcus Foundation, Ossium Health, Inc.
Asthma
07/25
12/25
NCT05241288: Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

Completed
N/A
54
US
Albuterol eMDPI DS, ProAir® Digihaler®
University of North Carolina, Chapel Hill, Wake Forest University Health Sciences, Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
02/23
02/23
NCT04912596: Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma

Recruiting
N/A
148
RoW
Albuterol Sulfate inhalation aerosol 108 mcg per actuation, Albuterol Sulfate, Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation, Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo, Albuterol Sulfate inhalation Placebo, Methacholine
Intech Biopharm Ltd.
Mild Asthma
01/25
06/25
ACTRN12613000836730: Albuterol for Acute Lung Injury

Recruiting
N/A
50
 
south valley university , south valley university, Qena university hospital
we will study the effect of adding aerosolized albuterol to lung recruitment maneuver during the managment of ALI due to surgical and non-surgical causes e.g acute lung injury following aspiration pneumonia , abdominal sepsis, pancreatitis, chest trauma , lobectomy,and so on
 
 
Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
2019-003082-17: How electronic monitoring and feedback affect use of Easyhaler asthma medication. Wie sich elektronische Kontrolle und Rückmeldung auf die Einnahme der Easyhaler-Asthmamedikation auswirken

Not yet recruiting
4
166
Europe
Inhalation powder, Budesonid Orion Easyhaler 0,2 mg/Dosis, Budesonid Orion Easyhaler 0,4 mg/Dosis, Bufori Easyhaler 160 Mikrogramm/4,5 Mikrogramm, Bufori Easyhaler 320 Mikrogramm/9 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/250 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/500 Mikrogramm, Salbu Easyhaler 0,2 mg/Dosis
Orion Corporation Orion Pharma, Orion Corporation Orion Pharma
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-001573-22: Use of Buventol and Bufomix Easyhaler in methacholine challenge andtheir effect on inhalation profiles in experimentally induced asthma attacks Buventol ja Bufomix Easyhalerin käyttö metakoliinialtistuksen avaavana lääkkeenä sekä niiden vaikutus sisäänhengitysprofiileihin kokeellisesti aiheutetussa astmakohtauksessa

Not yet recruiting
4
180
Europe
Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation pMDI, Inhalation powder, Inhalation solution, Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation
Orion Corporation, Orion Corporation
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
EASYRELIEF, NCT05084222 / 2021-001573-22: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

Completed
4
180
Europe
Buventol® Easyhaler® 200 µg/inhalation dmDPI, Salbutamol 200 µg/dose dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Budesonide/formoterol 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI, Salbutamol 100 µg/dose MDI
Orion Corporation, Orion Pharma, Orion Corporation
Asthma
06/23
06/23
budesonide/formoterol / Generic mfg.
ACTRN12622000232730p: Monitoring Intermittent vs Regular inhaled corticoSteroids in asthma: MIRSA study

Not yet recruiting
4
135
 
Dr John D Brannan, GlaxoSmithKline
Asthma
 
 
ACTRN12622000232730: Monitoring Intermittent vs Regular inhaled corticoSteroids in asthma: MIRSA study

Not yet recruiting
4
135
 
Dr John D Brannan, GlaxoSmithKline
Asthma
 
 
2005-005874-65: Non-invasive monitoring of airway inflammation in asthmatic patients during adaptation of inhaled steroid therapy

Ongoing
4
40
Europe
Symbicort Turbohaler, Inhalation powder
University Hospital Antwerp
asthma
 
 
ChiCTR-TRC-10000969: Chronic obstructive pulmonary disease(COPD): clinical study of Symbicort Turbuhaler combined Theophylline

Completed
4
100
 
Symbicort 160/4.5ug/breathing, 2 breathing/time, twice a day+theophylline 0.1g - 0.2g twice a day +Ventolin 100ug/breathing, prn ;Symbicort 160/4.5ug/breathing, 2 breathing/time, twice a day+Ventolin 100ug/breathing, prn
1st Affiliated Hospital of SYSU; Level of the institution：, s
Chronic obstructive pulmonary disease(COPD)
 
 
2014-001029-34: The inhaled combination of budesonide-formoterol consists a basic asthma treatment.A helpful specific index for the prognosis of future exacerbation risk and deterioration of lung function,is the Exhaled Nitric Oxide.The objective of the current study is the evaluation of Pulmoton- Elpenhaler in Exhaled Nitric Oxide of patients with bronchial asthma. Ο εισπνεόμενος συνδυασμός βουδεσονίδης-φορμοτερόλης αποτελεί τη βασική θεραπεία για το άσθμα. Ένας ειδικός δείκτης που βοηθά στην πρόγνωση μελλοντικού κινδύνου παρόξυνσης και μείωσης της λειτουργίας των πνευμόνων, είναι το εκπνεόμενο μονοξείδιο του αζώτου.Η παρούσα μελέτη έχει ως κύριο σκοπό την αξιολόγηση της επίδρασης του εισπνεόμενου συνδυασμού βουδεσονίδης-φορμοτερόλης (Pulmoton® Elpenhaler®) στο εκπνεόμενο μονοξείδιο του αζώτου ασθενών με βρογχικό άσθμα.

Ongoing
4
108
Europe
Pulmoton/Elpenhaler, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler, Pulmoton/Elpenhaler (200/6)mcg, Symbicort Turbuhaler
ELPEN Pharmaceutical Co. Inc, ELPEN Pharmaceutical Co. Inc.
Bronchial Asthma Bρογχικό Άσθμα
 
 
2018-003467-64: A 24-week Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using Salbutamol or AntiInflammatory Reliever (SYMBICORT®) as rescue medication in addition to SYMBICORT as daily asthma controller.

Not yet recruiting
4
80
Europe
Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, Inhalation powder, Symbicort® Turbohaler®
Astra Zeneca AB, Astra Zeneca AB
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ChiCTR1800020279: Clinical trial for step-down therapy in patients with mild to moderate asthma

Recruiting
4
100
 
budenide 200μg qd+SABA prn ;symbicort 80/4.5μg qd+prn ;symbicort 80/4.5μg prn ;symbicort 80/4.5μg prn ;SABA prn
West China Hospital, Sichuan University; West China Hospital, Sichuan University, latitudinal project funds
bronchial asthma
 
 
SHAMAL, NCT04159519 / 2019-001924-37: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed
4
170
Europe
Symbicort®, budesonide/formoterol, Fasenra®, benralizumab, Ventolin®, salbutamol
AstraZeneca
Asthma, Severe Eosinophilic Asthma
01/23
01/23
ChiCTR2100048845: Comparison of Budesonide, Symbicort and Triple Nebulized Drugs in Improving Perioperative Airway Function of Chronic Sinusitis

Recruiting
4
300
 
Budesonide ;Symbicort ;Triple Nebulized Drugs
Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital, National Natural Science Foundation of China (82071021)
chronic nasosinusitis
 
 
MIT-AIR, NCT06568445: Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy

Not yet recruiting
4
90
RoW
Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）, maintenance at initial treatment sequential as-needed therapy group, as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）, As-needed therapy group
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bronchial Asthma
04/27
09/27
NCT01225913: Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Recruiting
4
50
US
fluticasone/salmeterol in all asthmatics, symbicort 80/4.5, advair 100/50 or 250/50 or 500/50 bid, budesonide/formoterol or fluticasone/salmeterol in all asthmatics, symbicort 160/4.5, advair 250/50
Gelb, Arthur F., M.D.
Asthma
06/27
06/27
ChiCTR2400088138: Efficacy of ICS-Formoterol Maintenance at Initial Treatment with Sequential Anti-Inflammation Reliever Therapy in Newly Diagnosed Mild Asthma Patients: A Randomized, Parallel, Positive-Control Study

Not yet recruiting
4
90
 
Inhaled budesonide-formoterol as needed when symptoms are present (Symbicort 160/4.5) ?）， No more than 8 puffs per day, continuous to 24W.; budesonide 160 μg-formoterol 4.5 μg, administered as one inhalation twice daily for maintenance for 4W, sequential as-needed therapy to 24W.
Shanghai General Hospital; Shanghai General Hospital, Clinical Research Innovation Plan of Shanghai General Hospital;China International Medical Foundation-Practical Research Project on Respiratory Diseases
mild bronchial asthma
 
 
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme

Not yet recruiting
3
102
Europe
, Inhalation powder, pre-dispensed, Bricanyl, Symbicort
Centre Hospitalier Intercommunal de Créteil, Astrazeneca
moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ACTRN12622001217796: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma.

Recruiting
3
400
 
Medical Research Institute of New Zealand, AstraZeneca Ltd
Asthma
 
 
ChiCTR-TRC-08000215: Chronic obstructive pulmonary disease(COPD)--Symbicort Turbuhaler clinical study

Completed
3
450
 
Symbicort? 160/4.5ug/breathing, 2 breathing/time, 2 times/day+Symbicort?160/4.5ug/breathing, prn ;Symbicort 160/4.5ug/breathing, 2 breathing/time, 2 times/day + Turbuhaler 100ug/breathing, prn ;Si Lihua 18ug/breathing, 1 breathing/time, 1 time/day + Auccitub 12ug/breathing, 2 times/day, and Turbuhaler 100ug/breathing, prn
The First Affiliated Hospital of Sun Yat-sen University; 2nd and 3rd Affiliated Hospital of SYSU, Department of Statistics of School of Public Health of SYSU, Sun Yat-sen University
Chronic obstructive pulmonary disease(COPD)
 
 
ChiCTR-TRC-09000566: Mild Asthma--as-needed Symbicort Turbuhaler clinical study

Completed
3
450
 
one inhalation of Pulmicort Turbuhaler 200 ug/inhalation ;Oxis Turbuhaler 4.5 ug/inhalation with symptom-driving ;Symbicort Turbuhaler 160/4.5 ug/inhalation with symptom-driving
1st Affiliated Hospital of SYSU; 2nd and 3rd Affiliated Hospital of SYSU, 1st Affiliated Hospital of SYSU
mild asthma
 
 
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva.

Ongoing
3
200
Europe
Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG
GlaxoSmithKline Research and Development, GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
 
 
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma.

Ongoing
3
675
Europe
Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms
Medical Research Institute of New Zealand, Astra Zeneca
Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation

Terminated
3
102
Europe
Budesonide Formoterol Drug Combination, nebulisation of terbutaline
Centre Hospitalier Intercommunal Creteil, AstraZeneca
Asthma in Children
09/21
06/23
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

Completed
3
1485
US
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg
Cipla Ltd.
Asthma
08/23
08/23
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma

Completed
3
644
Europe, Canada, Japan, US, RoW
BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH
AstraZeneca
Asthma
02/25
02/25
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting
3
300
Europe, Canada, US, RoW
Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
AstraZeneca, Fortrea
Severe Asthma
06/27
06/27
KALOS, NCT04609878 / 2020-001520-34: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2266
Europe, Canada, Japan, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca, AstraZeneca AB
Asthma
03/25
03/25
LOGOS, NCT04609904 / 2020-001521-31: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma

Active, not recruiting
3
2182
Europe, US, RoW
BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort®
AstraZeneca
Asthma
03/25
03/25
ChiCTR2500098432: Single dose, fasting, randomized, open label bioequivalence study of budesonide fomotro inhaled aerosol in healthy subjects

Completed
1
40
 
T-R-T-R Test preparation (T): budesonide formoterol inhalation aerosol, the specification is the main drug content per bottle: 120 bottles per bottle, 181 g of budesonide per bottle, 5.1 g of formoterol fumarate, delivery dose: 120 bottles per bottle, 160 g of budesonide per bottle, 4.5 g of formoterol fumarate. Produced and supplied by Sichuan Pritech Pharmaceutical Co., Ltd. Reference preparation (R): budesonide formoterol inhalation aerosol (trade name: SYMBICORT?), specification is 120 puffs per bottle, each puff contains budesonide 181 g, formoterol fumarate 5.1 g, and 160 g of budesonide and 4.5 g of formoterol fumarate per pinch outside the driver. Produced by AstraZeneca and supplied by Sichuan Pritech Pharmaceutical Co., Ltd.; R-T-R-T Test preparation (T): budesonide formoterol inhalation aerosol, the specification is the main drug content per bottle: 120 bottles per bottle, 181 g of budesonide per bottle, 5.1 g of formoterol fumarate, delivery dose: 120 bottles per bottle, 160 g of budesonide per bottle, 4.5 g of formoterol fumarate. Produced and supplied by Sichuan Pritech Pharmaceutical Co., Ltd. Reference preparation (R): budesonide formoterol inhalation aerosol (trade name: SYMBICORT?), specification is 120 puffs per bottle, each puff contains budesonide 181 g, formoterol fumarate 5.1 g, and 160 g of budesonide and 4.5 g of formoterol fumarate per pinch outside the driver. Produced by AstraZeneca and supplied by Sichuan Pritech Pharmaceutical Co., Ltd.
Beijing Shijitan Hospital, Capital Medical University; Sichuan Purity Pharmaceutical Co., Ltd., Sichuan Purity Pharmaceutical Co., Ltd.
chronic obstructive pulmonary disease
 
 
ChiCTR1800017584: Efficacy and safety of tiotropium bromide combined with budesonide/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease

Completed
N/A
180
 
Budesonide/formoterol (Symbicort; 160 μg/4.5 μg; 1 suction/time, 2 times/day); treatment of tiotropium bromide (Spiriva; 1.8 μg inhaled once a day before sleeping). ;Bbudesonide/formoterol (Symbicort; 160 μg/4.5 μg; 1 suction/time, 2 times/day).
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, None
Moderate to severe chronic obstructive pulmonary disease
 
 
ChiCTR1800019852: The efficacy of budesonide/formoterol in cough variant asthma: A Multi-center Randomized, Controlled Clinical Trial

Recruiting
N/A
500
 
budesonide/formoterol (Symbicort) 160/4.5ug 2 inhalation bid* 3 months ;budesonide/formoterol (Symbicort) 160/4.5ug 1 inhalation bid* 3 months
Second Affiliated Hospital, Zhejiang University School of Medicine; Second Affiliated Hospital, Zhejiang University School of Medicine, support by AstraZeneca
cough variant asthma
 
 
ChiCTR2000030452: Multicenter prospective randomized controlled trial for Dong-Tian Chang-Chun Ointment in the treatment of stable COPD patients

Not yet recruiting
N/A
96
 
Dongtian Changchun Ointment+Symbicort Turbuhaler ;Symbicort Turbuhaler
Zhongshan Hospital Affiliated Fudan University; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Zhongshan Hospital Affiliated Fudan University, Key projects for prevention and control of chronic noncommunicable diseases in the 13th five-year plan of the ministry of science and technology
Chronic obstructive pulmonary disease
 
 
ChiCTR2000036980: Clinical study on the effect of Sansang Shenqi Decoction on airway function in patients with chronic obstructive pulmonary disease at stable period

Recruiting
N/A
200
 
Sansang Shenqi Decoction+Symbicort Turbuhaler ;Symbicort Turbuhaler
LongHua Hospital Shanghai University of Traditional Chinese Medicine; Level of the institution：, Shanghai Shenkang Hospital Development Center
chronic obstructive pulmonary disease
 
 
NCT06105671: U-LABA/ICS Effects on Exercise Performance, Formoterol

Completed
N/A
20
Europe
Symbicort, Formoterol, Placebo, Mannitol
Morten Hostrup, PhD
Exercise Performance
07/24
07/24
NCT00576069: Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting
N/A
60
US
budesonide/formoterol, symbicort 80/4.5, symbicort 160/4.5, budesonide 80 or 160ug/formoterol 4.5ug, 2 inhalations bid, spiriva handihaler or respihaler, fluticasone/salmeterol, advair 100/50, advair 250/50, mometasone/formoterol, Dulera, Prednisone, medrol
Gelb, Arthur F., M.D.
Asthma
06/27
06/27
Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
2022-003784-15: Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient. Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable.

Not yet recruiting
4
35
Europe
Trixéo Aerosphere, BGF 160, Suspension and solution for spray, Trixeo Aérosphère
CHU DE LILLE, AstraZeneca
Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable, Impact of inhaled BGF 160 on complexity and variability of tidal breathing and oscillatory mechanics in stable COPD patient Impact du traitement inhalé triple BGF 160 sur la complexité et la variabilité du mode ventilatoire et l’oscillométrie chez les patients BPCO en état stable, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT06571942: Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

Recruiting
4
128
RoW
Vilanterol / Umeclidinium (25/62.5 mcg), ANORO, Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), TRELEGY, Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg, TRIMBOW, Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg, TRIXEO
National Institute of Respiratory Diseases, Mexico
COPD Bronchitis, Pollution Related Respiratory Disorder
01/25
01/25
IKANOS, NCT05970263: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Withdrawn
4
1000
NA
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator
AstraZeneca, Iqvia Pty Ltd, Premier Inc.
COPD
12/25
12/25
NCT06905483: Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Not yet recruiting
4
28
RoW
Budesonide/Glycopyrronium/Formoterol (BGF), Breztri, Fluticasone Furoate/Umeclidinium/Vilanterol (FUV), Trelegy
Thammasat University
COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
12/25
03/26
INDOS-B, NCT06531798: Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

Not yet recruiting
4
150
NA
Breztri Aerosphere
AstraZeneca
Moderate to Severe COPD
10/26
12/26
2018-001704-10: Phase 3b Study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fuumarate and Glycopyrronium/Formoterol Fumarate on Specific Image based Airway Volumes and Resistance in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Not yet recruiting
3
20
Europe
Budesonide Glycopyrronium Formoterol Fumarate, Glycopyrronium Formoterol Fumarate (GFF), PT010, PT0003, Pressurised inhalation, suspension, Bevespi
AstraZeneca AB, AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD), Diseases [C] - Respiratory Tract Diseases [C08]
 
 
THARROS, NCT06283966: A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting
3
5000
Europe, Canada, Japan, US, RoW
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
03/28
03/28
NCT05573464 / 2022-001476-33: A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Hourglass Jul 2024 - Dec 2024 : Data for COPD
Completed
3
559
Europe, Canada, US, RoW
BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFO, BGF MDI HFA 320/14.4/9.6 μg, BGF MDI HFA
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
03/24
03/24
ATHLOS, NCT06067828: A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Recruiting
3
180
Europe, Canada, US, RoW
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
08/25
08/25
NCT06075095: A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

Recruiting
3
255
Europe, Canada, US, RoW
BGF MDI HFO 320/14.4/9.6μg, Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF), Delivered by MDI HFO (HFO-1234ze), BGF MDI HFA 320/14.4/9.6 μg, Delivered by MDI HFA, Placebo MDI HFA, Placebo
AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
09/25
09/25
VARI-OSCIL, NCT06110403: Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

Recruiting
1/2
35
Europe
TRIXEO AEROSPHERE
University Hospital, Lille, AstraZeneca
Copd
09/25
09/25
NCT05477108: Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Hourglass Jul 2023 - Dec 2023 : Data from trial in healthy volunteers
Completed
1
108
US
Treatment A (BGF MDI HFO with oral activated charcoal), Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFO, Treatment B (BGF MDI HFA with oral activated charcoal), Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
04/23
04/23
NCT05569421: A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Hourglass Feb 2024 - Jun 2024 : Data for healthy volunteers
Completed
1
108
US
Treatment A: BGF MDI HFO, Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFO, Treatment B: BGF MDI HFA, Budesonide/Glycopyronium/Formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
04/23
04/23
NCT06297668: A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Completed
1
42
Europe
Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO, AeroChamber Plus Flow-Vu spacer
AstraZeneca, Parexel
Chronic Obstructive Pulmonary Disease
06/24
06/24
NCT06340581: A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)

Withdrawn
1
132
NA
Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO, AeroChamber Plus Flow-Vu Spacer
AstraZeneca, Parexel
Healthy
02/25
02/25
NCT06723756: A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Recruiting
1
105
US
Treatment A: BGF MDI HFO, Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFO, Treatment B: BGF MDI HFA, Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFA
AstraZeneca, Parexel
Healthy Participants
06/25
06/25
NTproBNP, NCT06317428: NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Recruiting
N/A
29
Europe
Istituto Nazionale di Ricovero e Cura per Anziani
COPD
12/25
12/25
NCT06514144: Exacerbations Among Patients Receiving Breztri (EROS Study)

Completed
N/A
2409
US
BGF, Breztri
AstraZeneca
Pulmonary Disease, Chronic Obstructive, Retrospective Studies
03/23
03/23
ChiCTR2200060625: Perioperative use of budesonide/glycopyrrolate/formoterol MDI for cough relief in patients undergoing thoracic surgery

Not yet recruiting
N/A
30
 
Full use of budesonide/glycopyrrolate/formoterol (1 week before surgery, until discharge after surgery) ;budesonide/glycopyrrolate/formoterol was used postoperatively ;budesonide/glycopyrrolate/formoterol is not used
The first affiliated hospital zhejiang university school of medicine; The first affiliated hospital zhejiang university school of medicine, Third -party funding
Lung Cancer/Cough
 
 
OCT, NCT04675463: The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD

Not yet recruiting
N/A
50
RoW
BGF Inhalation Aerosphere, Breztri, GFF Inhalation Aerosphere, Bevespi
ShiYue Li, AstraZeneca
Pulmonary Disease, Chronic Obstructive
01/23
06/23
EBISU, NCT05219630: Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)

Completed
N/A
106
Japan
AstraZeneca
Pulmonary Disease, Chronic Obstructive
05/23
05/23
NCT05472350: Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After Lobectomy

Not yet recruiting
N/A
128
NA
Breztri Aerosphere, Placebo
Jianxing He
Lung Cancer, Nonsmall Cell, Perioperative, Cough, Drug Effect, Drug Toxicity
08/23
11/23
TORES, NCT04536402: Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

Completed
N/A
3520
RoW
AstraZeneca
Chronic Obstructive Pulmonary Disease
11/23
11/23
MINERVA, NCT06422676: MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA

Active, not recruiting
N/A
4
RoW
AstraZeneca
Chronic Obstructive Pulmonary Disease
12/24
12/24
SKOPOS:MAZI, NCT06744374: A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Completed
N/A
22369
US
BGF, Breztri, MITT, Open triple therapy combination
AstraZeneca
Pulmonary Disease, Chronic Obstructive
03/24
03/24
COnCORD, NCT06368427: Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

Recruiting
N/A
250
Europe
budesonide / glycopyrronium / formoterol
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
09/25
09/25
EROS+CP (US), NCT06742736: EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

Completed
N/A
13000
US
BGF, BREZTRI
AstraZeneca
Pulmonary Disease, Chronic Obstructive
09/24
09/24
RECORD, NCT05311306: REported Outcomes in COPD With Trixeo in Real worlD in Germany

Completed
N/A
475
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/24
07/24
ORESTES, NCT06321731: Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.

Completed
N/A
553
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
12/24
12/24
RECORD, NCT05213611: REported Outcomes in COPD With Trixeo in Real worlD

Completed
N/A
148
Europe
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/24
07/24
CHOROS, NCT06712563: Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Not yet recruiting
N/A
2000
NA
Budesonide/glycopyrrolate/formoterol fumarate, BGF, Breztri
AstraZeneca, Iqvia Pty Ltd
Pulmonary Disease, Chronic Obstructive
09/26
09/26
CHOROS ORION, NCT05862545: Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

Active, not recruiting
N/A
250
Europe
BGF (budesonide/glycopyrrolate/formoterol fumarate)
AstraZeneca
Chronic Obstructive Pulmonary Disease
07/25
07/25
TRIAENA, NCT05915182: Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

Active, not recruiting
N/A
218
Europe
Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
AstraZeneca
Pulmonary Disease, Chronic Obstructive (COPD)
05/25
05/25
Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
2019-003864-27: Effect of inhalation formulation on uncontrolled asthma

Not yet recruiting
4
70
Europe
Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta
HUS / Mika Mäkelä, Mika Mäkelä
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
AIRLYMPUS, NCT06676319: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Recruiting
2
1000
Europe, Canada, US, RoW
Lunsekimig, SAR443765, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/salmeterol, Budesonide/formoterol
Sanofi
Asthma
10/27
11/27
ChiCTR1800019111: An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects

Recruiting
1
36
 
FLUTIFORM pMDI single-dose administration (50/5 μg, 125/5 μg, and 250/10 μg) and multiple-dose administration (250/10 μg)
West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd
Asthma
 
 
Laevo-Bambuterol (R-bambuterol) / Alvogen
ChiCTR2100043100: Pharmacokinetic study of multiple oral administration of R-Bambuterol hydrochloride tablets in a population with higher plasma butylcholinesterase activity

Recruiting
1
50
 
R-BMB 5mg Q24 for 21 days ;R-BMB 5mg QN for 28 days ;R-BMB 10mg QN for 28 days
Dongguan People's Hospital; Key-Pharma Biomedical Inc., Self-finance
Asthma, COPD
 
 
Combivent (ipratropium/salbutamol) / Boehringer Ingelheim
ChiCTR-TRC-09000442: The effects of salmeterol/fluticasone on circulating biomarker in stable chronic obstructive pulmonary disease

Completed
4
122
 
Ipratropium/albnterol 36/206μg q.i.d (Combivent inhalation aerosol, Boehringer Ingelheim, Inc.) ;50 μg salmeterol and 500 μg fluticasone propionate (Advair Diskus, Seretide, GlaxoSmithKline)
West China Hospital; West China Hospital, Sekf-financing
Chronic obstructive pulmonary disease
 
 
ChiCTR-IPR-16008441: Clinical study on the prevention and treatment of acute altitude sickness by respiratory inhalation drugs

Completed
4
200
 
Budesonide; Ventolin ;Combivent ;physiological salt solution
The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army; The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army, sicentic fundation of the First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army
acute altitude sickness
 
 
2015-000473-12: The effectiveness of single dose Ultibro by Breezhaler versus ipratropium/salbutamol by nebulizer

Not yet recruiting
4
40
Europe
indacaterol maleate/glycopyrronium bromide, ipratropium/salbutamol, QVA149, Inhalation powder, hard capsule, Nebuliser liquid, Ultibro Breezhaler (indacaterol/glycopyrronium), Combivent, salbutamol/ipratropium
UMCG, UMCG, Novartis
COPD, chronic obstructive pulmonary disease, COPD, chronic obstructive pulmonary disease, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ChiCTR-IPR-15006319: Positive end-expiratory pressure device combined with ultrasonic nebulization on the sputum treatment of chronic obstructive pulmonary disease (COPD)

Recruiting
N/A
120
 
positive end-pxpiratory pressure device and combivent ;positive end-pxpiratory pressure device and saline ;ultrasonic nebulization and combivent ;oxgyen nebulization and combivent
The first affiliated hospital of guangzhou medical university; The First Affiliated Hospital of Guangzhou Medical University, NO
chronic obstructive pulmonary disease (COPD)
 
 
ChiCTR2000038403: A clinical study of nebulization of combivent and mannitol for the treatment of bronchiectasis

Recruiting
N/A
60
 
conventional therapy+combivent and mannitol nebulization ;conventional therapy+normal saline nebulization
The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Self financing
Bronchiectasis
 
 
Alenia (budesonide/formoterol) / Ache Lab
NCT02621359: A Two Week Nitazoxanidebased Quadruple Regimen

Recruiting
3
100
RoW
Nitazoxanide, Alenia, nitclean, parazoxanide, Levofloxacin, Tavanic, levoxin, venaxan., Doxycyclin, Vibramycin, Doxymycin, Omeprazole, Omepak, Pepzole, Gasec, Risek.
Tanta University
Dyspepsia
12/22
12/22
ESPIRE, NCT04233190: A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

Completed
3
472
RoW
Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg, fumarato de formoterol di-hidratado 12mcg + budesonida 400mcg/fumarato de formoterol di-hidratado 62mcg + budesonida 200mcg
Eurofarma Laboratorios S.A.
Asthma Copd
10/24
10/24
FORASMA, NCT05735431: Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil

Not yet recruiting
3
132
RoW
Administration of investigation drug, Formoterol 6 mcg/fluticasone 125 mcg, Administration of comparator, Alenia® 6 mcg/200 mcg
Eurofarma Laboratorios S.A.
Moderate Asthma
05/26
07/26
abediterol (AZD-0548) / AstraZeneca
2016-004140-10: A study to investigate the effects of different dose levels of abediterol administered once daily during four weeks to patients with symptomatic asthma on inhaled corticosteroids compared to patients given an open label comparator or placebo. The study will evaluate the efficacy of abediterol, how this study drug is absorbed in the blood stream and how safe and tolerable it is for the patients.

Ongoing
2
600
Europe, RoW
Abediterol, Serevent Accuhaler containing 50 micrograms of salmeterol (as xinafoate), AZD0548, Inhalation powder, Inhalation powder, pre-dispensed, Serevent Accuhaler
AstraZeneca AB, AstraZeneca AB
This study will be performed in men and non-pregnant, non-lactating women, all between 12 and 95 years of age with asthma symptomatic on ICS and fulfilling the reversibility criterion (improvement of FEV1≥12% and 200 mL after administration of salbutamol/albuterol) at Visit 2., Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that episodes of breathing difficulty are still occurring despite the use of other available treatments., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium

Not yet recruiting
3
28
Europe
QMF149, QVM149, Inhalation powder
University Medical Center Groningen, Novartis Pharma AG
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
3
200
Europe, RoW
QMF149, Budesonide
Novartis Pharmaceuticals
Asthma
05/26
06/26
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
 

Download Options